RxDoctor Payments Data

Madhavi Chary, MD

Family Medicine · Melbourne, FLNPI 1952544371

Payments from drug & device makers

$773in general payments, 2019–2025

Across 35 payments — averaging $22.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$270
  • Boston Scientific$112
  • Novo Nordisk$83
  • Pfizer$52
  • Exact Sciences$47
  • Novartis$38
  • plus $172 from 8 others

What the payments were for

  • Food & beverage$773100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$773 in reported general payments places this provider in the 60th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$74,012
Medicare patients
195
Services billed
791

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban41$39,569
OzempicSemaglutide29$35,755
JardianceEmpagliflozin16$15,920
MyrbetriqMirabegron11$8,080
Advair HfaFluticasone Propion/Salmeterol11$6,640
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$3,891
Albuterol Sulfate HfaAlbuterol Sulfate42$1,674
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,585
Gabapentin76$1,444
Losartan Potassium105$1,380
Atorvastatin Calcium109$1,309
Metoprolol Succinate83$1,280
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen122$1,101
Pantoprazole Sodium77$1,074
Levothyroxine Sodium65$1,049

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$52$39,56941 claims
Novo NordiskOzempic$83$35,75529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →